Tesamorelin: An Upstream Signal, Approved for One Specific Job

The short version

Tesamorelin doesn't supply growth hormone directly. It mimics growth hormone-releasing hormone (GHRH) — the signal the hypothalamus sends to the pituitary gland to release GH in its natural, pulsatile rhythm. By amplifying that upstream signal rather than replacing the hormone itself, tesamorelin aims to work with the body's own regulation rather than override it.

It is FDA-approved, specifically to reduce excess abdominal (visceral) fat in people with HIV-associated lipodystrophy — a fat-redistribution condition linked to antiretroviral therapy. In the trials behind that approval, it measurably shrank visceral fat and, in later work, liver fat too ^[6][8]. A recent meta-analysis pooling five randomized trials confirmed those effects while also finding an increase in lean body mass ^[6].

That approval is narrow by design: it covers one population and one fat depot, not general-purpose weight loss. This page describes exactly what was studied, and recommends no dose for any use.

What it is

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone, GHRH(1-44), with a trans-3-hexenoic acid group attached to its N-terminus. That modification is the whole trick: it blocks the enzyme dipeptidyl peptidase-IV (DPP-IV) from rapidly chopping up the peptide, which is what happens to natural GHRH within minutes. The result is a molecule stable enough to be given as a once-daily subcutaneous injection.

Its free-base molecular formula is C221H366N72O67S; the clinically supplied form is the acetate salt. Structurally and functionally, it is designed to look like the body's own releasing hormone to the pituitary gland — not to add growth hormone from outside, but to make the body release more of its own, in its usual pulsed pattern.

How it works

Tesamorelin binds the growth hormone-releasing hormone receptor (GHRH-R) on somatotroph cells in the anterior pituitary gland, switching on a signaling cascade (Gs protein, adenylyl cyclase, cyclic AMP, protein kinase A) that triggers those cells to synthesize and release growth hormone in pulses. That GH then travels to the liver, where it drives production of insulin-like growth factor-1 (IGF-1) — together, GH and IGF-1 promote lipolysis (fat breakdown), preferentially in visceral fat.

Because tesamorelin amplifies an existing, tightly regulated feedback loop rather than delivering GH directly, its metabolic footprint differs from injecting recombinant growth hormone itself. In a small trial in healthy men, two weeks of tesamorelin measurably raised both overnight GH and IGF-1 without significantly changing fasting glucose or insulin-stimulated glucose uptake ^[9] — an early signal that the visceral-fat effect doesn't necessarily come at the cost of worsened glucose handling, at least over that short window.

What the research shows

Pooled trial evidence. A 2026 meta-analysis of five randomized controlled trials in HIV-associated lipodystrophy found tesamorelin significantly reduced visceral adipose tissue (mean difference -27.71 cm2), trunk fat (-1.18 kg), and hepatic fat fraction (-4.28%), while increasing lean body mass (+1.42 kg) — all differences statistically significant, without serious adverse events ^[6].

The pivotal JAMA trial. In a 6-month randomized trial of 50 antiretroviral-treated adults with HIV, tesamorelin 2 mg/day produced a treatment effect of -42 cm2 in visceral fat (P=0.005) and reduced hepatic lipid content by a net -2.9% (P=0.003) — one of the first controlled demonstrations that the visceral-fat effect extends to liver fat as well ^[8].

52-week durability, and what happens on stopping. Across a year-long program (273 on tesamorelin, 137 on placebo), the visceral-fat reduction held at roughly -18% versus baseline, and glucose parameters over that year were not clinically significant — but visceral fat reaccumulated once tesamorelin was stopped, underlining that the effect depends on continued treatment ^[10].

Mechanism confirmation in healthy men. A short two-week trial in 13 healthy men confirmed the GH- and IGF-1-raising effect described above, without a significant change in glucose handling over that period ^[9].

Regulatory and liver-safety record. Tesamorelin was approved in the U.S. in 2010 for HIV-associated lipodystrophy. The NIH's LiverTox monograph rates it a Class E likelihood for drug-induced liver injury — meaning it is considered an unlikely cause of clinically apparent liver injury, with no attributable cases reported in trials ^[7].

Reported effects, cautions & safety

Tesamorelin's evidence base here comes almost entirely from a defined clinical trial program in a specific population — HIV-associated lipodystrophy — rather than from years of broad, informal community use the way tirzepatide's has accumulated. That means this page has less forum-sourced, anecdotal material to draw on than its neighbors, and none is invented here. What follows are the cautions the trial and monograph literature itself supports.

Cited cautions from the clinical literature:

• Approval is narrow. Tesamorelin is FDA-approved specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy ^[7]. Any other use — general visceral-fat reduction outside that population, anti-aging, or cognitive uses — falls outside its approved indication.
• The effect is not permanent. Visceral fat measurably reaccumulates once treatment stops, so any benefit depends on continued use rather than a one-time course ^[10].
• It raises IGF-1, a growth factor. Trials over roughly a year did not show an excess malignancy signal, but active malignancy is a labeled contraindication, and long-term oncologic safety data beyond a year are limited ^[9].
• Glucose parameters bear watching. Short- and longer-term trials did not find clinically significant glucose changes, but the mechanism (raising GH, an insulin-antagonist hormone) is one where monitoring is reasonable in anyone with pre-existing dysglycemia ^[9][10].
• It is prohibited in sport. As a GHRH analogue, tesamorelin falls under the WADA Prohibited List (Section S2), in- and out-of-competition.

Where it fits in Metabolic & Weight Research

Tesamorelin occupies the middle ground on this desk: real, replicated, statistically significant trial results ^[6][8][10] — but for a specific fat depot in a specific population, not general weight management. It is the most narrowly targeted of the three compounds and, not coincidentally, the one with the cleanest mechanistic story tying an upstream hormonal signal to a measured downstream fat change. Where AOD-9604 promised a similar upstream-fragment logic but failed its human obesity endpoint, tesamorelin's GHRH-amplification approach delivered a reproducible, FDA-recognized result — just a narrower one than tirzepatide's. See the comparison page for the full picture.